Davis Polk & Wardwell LLP advised J.P. Morgan Securities Inc. as sole book-running manager on an SEC-registered offering of 5,642,280 shares of common stock of BioMimetic Therapeutics, including 642,280 shares from the partial exercise of the underwriters’ over-allotment option. The net proceeds of the offering were approximately $39.8 million.

BioMimetic Therapeutics is a biotechnology company, which develops and commercializes innovative products to help stimulate the body’s natural tissue regenerative process. Its shares trade on the Nasdaq Global Stock Market under the symbol “BMTI.”

The Davis Polk corporate team included partner Richard D. Truesdell Jr. and associates Y. Jung Choi, Peter E. Devlin and Christopher R. Bornhorst. Partner Steven S. Weiner and associate David R. Bauer provided intellectual property advice. Partner William H. Weigel and associate Niya Tang provided tax advice. Partner Gail A. Flesher and associate Emma L. Ahrens provided environmental advice. Jack S. Keating was the legal assistant on the transaction. All members of the Davis Polk team are based in the New York office, except for Mr. Weiner who is based in Menlo Park.